Anti-Human Endostatin-Anti-Human Endostatin-一抗-艾美捷科技有限公司

PRODUCT CENTER

一抗

产品中心

当前位置：首页 > 产品中心 > 免疫学产品 > 一抗

背景资料: Endostatin, an endogenous non-glycosylated inhibitor of endothelial cell proliferation and angiogenesis, is an approximately 181 amino acid (aa), 20 kDa proteolytic fragment of the C-terminal non collagenous domain of type XVIII collagen. It is produced and/or trimmed by metalloproteinases such as MMP2 and MMP9, and cathepsins S, B and L. The Nterminal ~27 aa of Endostatin appear to contain the majority of its activity. This region contains three zinc binding sites that are thought to be critical for its anti-endothelial and ant-itumor effects, as well as multiple cleavage sites that, when used, can modify its activity. Human Endostatin shares 84-87% aa sequence identity with mouse, rat, bovine and equine Endostatin. Endostatin inhibits endothelial cell growth by inducing cell cycle arrest in G1 phase and initiating apoptosis. It is also thought to downregulate angiogenesis by blocking VEGF-induced endothelial cell migration. It alters the effect of FGF basic on adhesion and cell motility. Endostatin can interact with Transglutaminase 2, heparin, and integrins α5β1 and αv β3, all of which may be secreted by, or expressed on, endothelial cells, and can influence adhesion or migration.

保存建议: 该Anti-Human Endostatin的详细信息查看ReliaTech提供的产品说明书。溶解建议：Centrifuge vial prior to opening. Reconstitute in sterile water to a concentration of 0.1-1.0 mg/ml.

其他: ReliaTech全称为受体配体技术有限公司 (Receptor Ligand Technologies GmbH)，1999年成立，总部位于德国不伦瑞克，是一家后基因组生物技术公司。ReliaTech主要专注于受体和配体的发现与研究。此外，ReliaTech也开发应用于血管与淋巴管生成研究的相关高品质试剂。目前ReliaTech提供近2800款产品，产品线主要包括重组蛋白(细胞因子、生长因子、可溶性受体)、抗体、ELISA试剂盒等。